<DOC>
	<DOCNO>NCT00004916</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness ifosfamide , teniposide , paclitaxel treat patient relapse non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Ifosfamide , Teniposide , Paclitaxel Treating Patients With Relapsed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity associate combination ifosfamide , teniposide , weekly paclitaxel patient relapse non-Hodgkin 's lymphoma . - Evaluate response rate time disease progression patient treat regimen . OUTLINE : This dose escalation study teniposide . Patients stratify accord whether proceed stem cell transplant . Patients receive ifosfamide IV 1-2 hour day 1-3 every 3 week , teniposide IV 2 hour day 1 every 3 week , paclitaxel IV 1 hour weekly . Patients candidate stem cell transplant continue treatment 120 day absence disease progression unacceptable toxicity . Patients proceed stem cell transplant continue treatment 36 day . Peripheral blood stem cell ( PBSC ) may harvest time autologous transplant plan . Transplant patient may continue chemotherapy proceed autologous allogeneic PBSC transplant . Cohorts 3-5 patient receive escalate dos teniposide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 3 5 patient experience dose limit toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 15-50 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intermediate high grade nonHodgkin 's lymphoma No lymphoblastic small cleave lymphoma Progressive disease follow doxorubicin base chemotherapy No 2 prior treatment regimen Measurable evaluable disease NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No significant cardiac disease Other : Not pregnant nursing Fertile patient must use effective contraception No active uncontrolled second malignancy No medical problem would preclude therapy HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Prior stem cell transplant allow Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
</DOC>